Clinical trials: Hepatic Chemotherapy
Cholangiocarcinoma
Efficacy and Safety of Hepatic Arterial Infusion Chemotherapy Combined With Tislelizumab and Regorafenib as First-Line Therapy for Advanced Cholangiocarcinoma
The goal of this clinical trial is to evaluate the efficacy and safety of hepatic arterial infusion chemotherapy (HAIC) combined with tislelizumab and regorafenib as first-line therapy in patients with locally advanced or…
- Trial name
- NCT07619937
- Testing
- HAIC Combined with Tislelizumab and Regorafenib
- Where
- China
- Volunteers
- 31 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
Sinusoidal Obstruction Syndrome
Sinusoidal Obstruction Syndrome for Stem Cell Transplant Patients Biomarker Study
The goal of this is to learn more about stem cell transplant and complications that some people have after their transplants, in particular sinusoidal obstruction syndrome (SOS), also called veno-occlusive disease of the liver.
- Trial name
- SOSBiomarker (NCT03132337)
- Testing
- Serial Blood Draws
- Where
- 4 sites in United States
- Volunteers
- 80 people
- Sponsor
- Indiana University
Hepatic Impairment, Healthy Volunteers
A Study to Evaluate the Effect of Hepatic Impairment on the Single Dose Pharmacokinetics (PK) of Intravenous TAK-954
The purpose of this study is to evaluate the effect of varying degrees of hepatic function on the single dose PK of IV TAK-954.
- Trial name
- NCT03277274
- Testing
- TAK-954
- Where
- 2 sites in Czechia, Slovakia
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Takeda
Hepatocellular Carcinoma, Atezolizumab Plus Bevacizumab
Low-Dose Bevacizumab and Atezolizumab Combined With TACE-HAIC in Unresectable Hepatocellular Carcinoma
This is a prospective, single-arm, phase II clinical study designed to evaluate the efficacy and safety of low-dose bevacizumab plus atezolizumab combined with transarterial chemoembolization followed by hepatic arterial infusion…
- Conditions
- Hepatocellular Carcinoma, Atezolizumab Plus Bevacizumab, Transarterial Chemoembolization
- Trial name
- NCT07543510
- Testing
- TACE-HAIC + Atezolizumab + Low-dose Bevacizumab
- Volunteers
- 38 people
- Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
Carcinoma, Hepatocellular
Study of Folfox4 Chemotherapy Regimen to Prevent Early Postoperative Recurrence for HCC-PVTT Patients
This study is to investigate the efficacy and safety of Folfox4 chemotherapy regimen to prevent early recurrence for hepatocellular carcinoma patients with portal vein tumor thrombus following curative resection
- Trial name
- NCT02813096
- Testing
- folfox4 chemotherapy regimen
- Volunteers
- 500 people
- Sponsor
- Guangxi Medical University
Hepatocellular Carcinoma
HAIC of FOLFOX vs. HAIC of OXA for Advanced HCC
The purpose of this study is to evaluate the efficacy and safety of hepatic arterial infusion chemotherapy (HAIC) of oxaliplatin plus fluorouracil/leucovorin compared with HAIC of oxaliplatin alone in patients with hepatocellular…
- Trial name
- NCT03468231
- Testing
- Sorafenib, HAIC of FOLFOX, HAIC of OXA
- Where
- 7 sites in China
- Volunteers
- 300 people
- Sponsor
- Sun Yat-sen University
Intrahepatic Cholangiocarcinoma
A Single Arm, Single Centered Phase II Trial on the Combination of Adebrelimab, Surufatinib and Irinotecan Liposome-based HAIC in Advanced iCC
Southeast Asia and China have the highest incidence of intrahepatic cholangiocarcinoma worldwide, with limited treatment options and large unmet medical needs.
- Trial name
- NCT06375642
- Testing
- Adebrelimab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Hepatecellular Carcinoma, RALOX-HAIC（Hepatic Arterial Infusion Chemotherapy With Raltitrexed and Oxaliplatin
QL1706 in Combination With Bevacizumab and RALOX HAIC for Hepatocellular Carcinoma With Vp3/4 PVTT
The goal of this prospective, single-arm, multi-center Phase II clinical trial is to evaluate the clinical efficacy and safety of QL1706 combined with bevacizumab and RALOX hepatic artery infusion chemotherapy in treating liver…
- Conditions
- Hepatecellular Carcinoma, RALOX-HAIC（Hepatic Arterial Infusion Chemotherapy With Raltitrexed and Oxaliplatin, Bevacizumab, Type VP3/4 Portal Vein Tumor Thrombosis
- Trial name
- NCT07327788
- Testing
- Iparomlimab and Tuvonralimab Injection (QL1706), Bevacizumab, Hepatic Arterial Infusion Chemotherapy with Raltitrexed and Oxaliplatin (RALOX-HAIC)
- Where
- China
- Volunteers
- 38 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Colo-rectal Cancer, Liver Metastases
A Study of Systemic Chemotherapy With CPT-11 Plus HAI (FUDR+L-OHP) in Patients With Initially Unresectable CRCLM
The aim of the trial is to optimize response rates and rates of secondary resections of metastases in patients with initially non-resectable metastatic colorectal cancer Liver Metastasis.
- Trial name
- NCT03493061
- Testing
- Irinotecan, Oxaliplatin, Floxuridine
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Sun Yat-sen University
Hepatocarcinoma
HAIC Combined With Anlotinib and TQB2450 as Adjuvant Therapy in HCC Patients With High Risk of Recurrence After Resection
This is a single center, non-randomized, open, multi-cohort clinical, exploratory Phase II study, to evaluate the efficacy and safety of HAIC combined with TQB2450 and anlotinib as adjuvant therapy in hepatocellular carcinoma…
- Trial name
- NCT05311319
- Testing
- HAIC+TQB2450+Anlotinib
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Fudan University
Metastatic Colorectal Cancer, Liver Metastases
Optimal Control of Liver Metastases From Colorectal Cancer With Cetuximab and Hepatic Artery Infusion of Chemotherapy
The primary objective of the study is to increase by 15% the complete macroscopic resection rate of predominantly liver metastases from metastatic colorectal cancer through combining systemic cetuximab and hepatic artery infusion…
- Conditions
- Metastatic Colorectal Cancer, Liver Metastases, Hepatic Lesions
- Trial name
- OPTILIV (NCT00852228)
- Testing
- IV cetuximab, HAI chronomodulated chemotherapy, HAI conventional chemotherapy
- Where
- 14 sites in Belgium, France and 2 more
- Volunteers
- 60 people
- Sponsor
- Association pour la Recherche sur le Temps Biologique et la Chronothérapie
Colorectal Liver Metastasis
Hepatic Arterial Infusion Chemotherapy Combined With Sintilimab and Regorafenib as Adjuvant Therapy for Colorectal Liver Metastasis Patients With a High Risk of Recurrent: a Single-arm, Phase II Study
Pts with histologically confirmed CRLM and whose CRS >2 were enrolled into this single-arm, phase II study. The critical enrollment criteria were that Subjects had completely resected Primary lesion and liver metastases and had…
- Trial name
- NCT05753163
- Testing
- HAIC-FOLFOX combined with Sintilimab and Regorafenib
- Where
- China
- Volunteers
- 44 people
- Sponsor
- Fudan University
Liver Metastasis Colon Cancer
Treatment With Hepatic Arterial Infusion of Oxaliplatin in Combination With Systemic FOLFIRI Chemotherapy and Bevacuzimab in Patients With Liver-only Colorectal Liver Metastases (CRLM): Conversion to Complete Resection in Patients With Initially Inoperable Liver-only CRLM.
A few studies have documented that some patients can be down-staged from an initially inoperable state to a potentially resectable state.
- Trial name
- NCT04003792
- Testing
- oxaliplatin, FOLFIRI Protocol, Bevacizumab
- Where
- Israel
- Volunteers
- 49 people
- Sponsor
- Rabin Medical Center
Hepatocellular Carcinoma, Lenvatinib
Lenvatinib vs Bevacizumab Plus ICIs and HAIC in Unresectable HCC
Previous studies had suggested hepatic arterial infusion chemotherapy (HAIC) combined with immune checkpoint inhibitors (ICIs) and anti-angiogenic drugs had promising anti-tumor activity in unresectable hepatocellular carcinoma…
- Trial name
- NCT06435013
- Testing
- Lenvatinib
- Where
- China
- Volunteers
- 208 people
- Sponsor
- Sun Yat-sen University
Colorectal Cancer, Pancreatic Cancer
Quality of Life of Patients Over 75 Yars Undergoing Palliative Chemotherapy
The aim of this research is to evaluate the quality of life of patients over 75 years of age undergoing palliative chemotherapy for digestive cancer.
- Conditions
- Colorectal Cancer, Pancreatic Cancer, Biliary Cancer, Hepatic Cancer
- Trial name
- EQLVCPAL (NCT04517448)
- Where
- France
- Volunteers
- 31 people
- Sponsor
- Centre Hospitalier de la côte Basque
Wilson Disease
Establishment of Human Cellular Disease Models for Wilson Disease
Establishment of human cellular disease models for Wilson disease for an individualized therapy develop-ment having the capacity to address both hepatic and neurologic forms of the disease
- Trial name
- IPSWILSON (NCT03867526)
- Where
- Pakistan
- Volunteers
- 40 people
- Sponsor
- CENTOGENE GmbH Rostock
Liver Cancer
Hepatic Arterial Chemoembolization With Cisplatin or Internal Radiation Therapy in Treating Patients With Advanced Liver Cancer That Cannot Be Removed By Surgery
RATIONALE: Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00109954
- Testing
- cisplatin, brachytherapy, yttrium Y 90 glass microspheres
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- University of Pittsburgh
HCC - Hepatocellular Carcinoma
The DoHAICs Study Expansion Phase
We explored the efficacy and safety of the first-line treatment of unresectable hepatocellular carcinoma with donafenib combined with hepatic artery infusion chemotherapy (HAIC) and sintilimab .
- Trial name
- NCT07584018
- Testing
- Donafenib, sintilimab, HAIC
- Volunteers
- 90 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Gastroesophageal Varices Hemorrhage, Colorectal Cancer
Oxaliplatin-induced Portal Hypertension
Oxaliplatin has been used as the first choice for the adjuvant chemotherapy of colorectal cancer and it has significantly improved the outcomes in patients with colorectal cancer.
- Conditions
- Gastroesophageal Varices Hemorrhage, Colorectal Cancer, Received Oxaliplatin-based Chemotherapy
- Trial name
- NCT04524676
- Testing
- Individualized Treatment
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Shanghai Zhongshan Hospital
Hepatocellular Carcinoma
Prospective Real-World Study of HAIC With Raltitrexed or 5-Fluorouracil for the Treatment of Hepatocellular Carcinoma
This study is a prospective cohort study aimed at comparing the efficacy and safety of RALOX-HAIC and FOLFOX-HAIC in the treatment of hepatocellular carcinoma.
- Trial name
- NCT06519578
- Testing
- hepatic artery infusion chemotherapy
- Where
- 2 sites in China
- Volunteers
- 1,115 people
- Sponsor
- RenJi Hospital